Document:

EXHIBIT 10.1
​
[***] Certain information in this exhibit has been omitted because it is permitted to be omitted by applicable regulatory guidance.
​
Execution Version
Confidential

​

​
​
​
February 9, 2022
​
SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
Level 13, Building 2, Nos. 36 and 58, Hai Qu Road,
Shanghai, China 201203
Attention: CEO
CC: Board Secretary, Securities Department
​
​
Re: Extension of Right of Reference Under License Agreement between Coherus and Junshi.
​
Ladies and Gentlemen: 
​
Reference is hereby made to that certain Exclusive License and Commercialization Agreement, dated February 1, 2021, between Coherus Biosciences, Inc. (“Coherus”) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi”), as the same may be amended from time to time (the “License and Commercialization Agreement”).  All capitalized terms used but not defined herein will have the meaning set forth in the License and Commercialization Agreement. [***].
​
[***] Coherus and Junshi execute this letter agreement (this “Letter Agreement”), memorializing their agreement to the following:
​
	1.	Grant of Right of Reference. Coherus hereby grants to Junshi the right to extend the rights granted to Junshi in Section 5.5 (Right of Reference) in the License and Commercialization Agreement to up to [***] of Junshi Territory Licensees [***].

​
		(a)	Grant of Right of Reference. Upon Junshi’s extension thereof to a Junshi Territory Licensee, Junshi will notify Coherus in writing and such Junshi Territory Licensee, its Affiliates, and the direct sublicensees of such Junshi Territory Licensee of the Licensed Technology (each, a “Junshi Territory Right of Reference Entity (JTRRE)”) will have, and Coherus grants to such JTRREs, a right of reference for use only in the Junshi Territory to all Regulatory Approvals and Regulatory Materials pertaining to the Licensed Products in the Field Controlled and submitted by or on behalf of Coherus or its Affiliates. 

		(b)	Timing of Extension.  Junshi may only extend its rights granted in Section 5.5 (Right of Reference) of the License and Commercialization Agreement with respect to Regulatory 

- 1 -
​
US-DOCS\131166251.5

 ​

			Materials Controlled by Coherus with respect to a Licensed Product upon and after submission for Regulatory Approval of the subject Licensed Product.

		(c)	Limitations on Use.  Each JTRRE may use such right of reference to such Regulatory Approvals and Regulatory Materials Controlled by Coherus or any of its Affiliates solely for the purpose of seeking, obtaining, supporting, and maintaining Regulatory Approval and any Pricing and Reimbursement Approvals of the Licensed Products in the Junshi Territory. Further, each JTRRE (A) may only rely on those portions of any such Regulatory Approvals or Regulatory Materials Controlled by Coherus or any of its Affiliates to the extent related to the Licensed Products that contain a Licensed Antibody and (B) may not rely on or have any right of reference with respect to those portions of any such Regulatory Approval or Regulatory Material to the extent relating to any product Controlled by Coherus or any of its Affiliates that is not a Licensed Product or to the active ingredient of any Combination Product or Combination Regimen that is not a Licensed Antibody.

		(d)	Costs.  As between the Parties, [***] will [***] bear the costs and expenses of [***] as provided in [***] the License and Commercialization Agreement.

		(e)	Further Actions.  Coherus will take such actions as may be reasonably requested by Junshi or its Affiliate to give effect to the intent of the extension of the right of reference made hereby and to give Junshi, its Affiliates and the JTRREs the benefit of Coherus’ and its Affiliates’ Regulatory Approvals and Regulatory Materials in the Junshi Territory as provided herein [***].

	2.	Data Sharing and Reports. In consideration for the extension of the grant of the right of reference to each Junshi Territory Licensee pursuant to the terms of Section 1 (Grant of Right of Reference) above, Junshi will cause each Junshi Territory Licensee to agree in writing to comply with, and provide to Junshi for providing to Coherus the same data, reports, and information required to be provided by Junshi to Coherus under [***] the License and Commercialization Agreement. Accordingly, if Junshi desires to extend such right of reference to a Junshi Territory Licensee, then it must do so on the following conditions:

​
		(a)	Data Use and Exchange.  The terms of an agreement between Junshi or its Affiliate and the Junshi Territory Licensee (“Junshi Territory Licensee Agreement”) must require the Junshi Territory Licensee to provide Junshi with copies of all data and results and all supporting documentation (e.g., protocols, Investigator’s Brochures, case report forms, analysis plans) that are generated by or on behalf of JTRREs in the Development of any Licensed Product For the Coherus Territory [***], except to the extent any such disclosure would be prohibited by any applicable law; provided, however, that in the case of a Combination Regimen in which any of the Other Component(s) is/are Controlled by a JTRRE (including when any such Other Component(s) is/are still in Development or the subject of one or more Regulatory Approval(s), a “Proprietary Combination Regimen”), each JTRRE is only required to disclose such data and results about the Licensed Product portion of the Proprietary Combination Regimen.  The terms of the Junshi Territory Licensee Agreement must also permit Junshi to provide a copy of such data, results, and documentation to Coherus, except to the extent any such disclosure would be prohibited by any applicable law.  Subject to Section 3 (Development Cost Sharing), Coherus will have the right to use and reference such data and results provided by Junshi for the purpose of obtaining, supporting, and maintaining Regulatory Approvals, as applicable, of the Licensed Products (but not any other part of a Proprietary Combination Regimen, if applicable) in the Coherus Territory [***].  The Junshi Territory Licensee Agreement must 

2
​
US-DOCS\131166251.5

 ​

			also require that if a JTRRE obtains the right to use or a right of reference to data Controlled by a Third Party with respect to a Combination Regimen, then the JTRRE must attempt to obtain sufficient rights from such Third Party to grant a further right to use or right of reference with respect to such Third Party data consistent with the foregoing rights to data and results generated by or on behalf of the JTRRE (i.e., the right of the JTRRE to extend such rights to Junshi and the right of Junshi to further extend such rights to Coherus).

		(b)	Development Records.  The Junshi Territory Licensee Agreement must require the applicable JTRREs to maintain reasonably complete, current, and accurate records of all Development activities conducted by or on behalf of the applicable JTRREs and subcontractors, respectively, for any Licensed Product (including any Combination Regimen) For the Coherus Territory and all data and other information resulting from such activities consistent with its usual practices, in validated computer systems that are compliant with 21 C.F.R. §11 and in accordance with applicable law in the Coherus Territory.  The Junshi Territory Licensee Agreement must also require the applicable JTRREs to maintain all such records relating to the Development of Licensed Products for a period of [***] years, or a longer period as may be required by applicable law or regulation, after the end of the Term.  The Junshi Territory Licensee Agreement must also require the applicable JTRREs to document all non-clinical and preclinical studies and Clinical Trials in formal written study reports in accordance with GLP, cGMP, and GCP in compliance with ICH Guidelines, as applicable, and in compliance with applicable law.  The Junshi Territory Licensee Agreement must also require that, upon Coherus’ reasonable request to Junshi, not more frequently than [***] each Calendar Year during which JTRREs or subcontractors are performing or having performed Development activities for any Licensed Product (including any Combination Regimen) For the Coherus Territory, the Junshi Territory Licensee will, and will cause the applicable JTRREs and subcontractors to, provide copies of such records (including access to relevant databases) to Junshi, and permit Junshi to provide copies of such records to Coherus upon receiving them from any Junshi Territory Licensee, in each case, except to the extent any such disclosure would be prohibited by any applicable law. Junshi will provide a copy of such records to Coherus promptly upon receipt from any Junshi Territory Licensee, except to the extent any such disclosure would be prohibited by any applicable law.

		(c)	Development Reports.  The Junshi Territory Licensee Agreement must require that at each joint development committee or similar meeting between Junshi or its Affiliate and any Junshi Territory Licensee at a time when Junshi Territory Licensee is performing, or having performed, Development activities for any Licensed Product (including any Combination Regimen) For the Coherus Territory, Junshi Territory Licensee must provide a report to Junshi summarizing the Development activities for the Licensed Products performed For the Coherus Territory during the period since the preceding meeting, the Development activities for the Licensed Products For the Coherus Territory in process, and the future Development activities for the Licensed Products For the Coherus Territory that any JTRREs or subcontractors expect to initiate, including a summary of the data, timelines, and results of such Development activities, in each case, except to the extent any such disclosure would be prohibited by any applicable law.  The Junshi Territory Licensee Agreement must also permit Junshi to disclose the foregoing to Coherus, except to the extent any such disclosure would be prohibited by any applicable law. Such reports and any additional information provided by Junshi regarding such Development activities for the Licensed Products For the Coherus Territory, in each case, will be the Confidential Information of Junshi and subject to the terms of Article 12 (Confidentiality) of the License and Commercialization Agreement.

3
​
US-DOCS\131166251.5

 ​

		(d)	Adverse Event Reporting.  The Junshi Territory Licensee Agreement must require that no later than [***] days after the effective date of the Junshi Territory Licensee Agreement, and in any event before the conduct of any Clinical Trial by the applicable JTRRE For the Coherus Territory, Junshi and the Junshi Territory Licensee to develop and agree in a written agreement on worldwide safety and pharmacovigilance procedures for Junshi and the Junshi Territory Licensee with respect to all Licensed Products, such as safety data sharing and exchange, adverse events reporting and prescription events monitoring (the “Junshi Territory Licensee PV Agreement”) that is consistent with the terms of the Pharmacovigilance Agreement under the License and Commercialization Agreement. The Junshi Territory Licensee Agreement must also require that the Junshi Territory Licensee PV Agreement will contain terms no less stringent than those required by ICH or other applicable guidelines in order to allow the Parties and the Junshi Territory Licensee to meet the applicable law and other applicable regulatory requirements regarding the management of safety data in the Coherus Territory.

		(e)	Enforcement. Junshi must enforce the foregoing provisions required to be included in the Junshi Territory Licensee Agreement against violations thereof by the Junshi Territory Licensee. 

	3.	Development Cost Sharing.  

		(a)	Junshi will include Development activities by each JTRRE for any Licensed Product (including any Combination Regimen) For the Coherus Territory and budget of the costs and expenses to be incurred in the performance such activities (“JTRRE Development Plan”) [***]. Coherus’ payments for the right to use and reference data and results granted under Section 2(a) (Data Use and Exchange) will be according to the amounts specified to be due under [***] the License and Commercialization Agreement, as applicable.

		(b)	Notwithstanding the foregoing, if Junshi is prevented by applicable law or Junshi’s contractual obligations to any Third Party from including the JTRRE Development Plan in the manner specified in section 3(a), then the Parties shall agree in writing the amounts of payments [***] will pay to [***] for the right, if desired by [***], to use and reference data and results granted under Section 2(a) (Data Use and Exchange) independent of the amounts specified to be due under [***] the License and Commercialization Agreement. 

	4.	[***] 

​
	5.	[***] Junshi will cause each JTRRE that is granted rights in [***] to agree to [***] that will restrict such JTRRE’s ability to [***].

​
	6.	Miscellaneous.

​
		(a)	Governing Law. This Agreement will be governed by, and enforced and construed in accordance with, the laws of the State of New York, without regard to its conflicts of law provisions.

		(b)	Assignment of this Letter Agreement.  Neither this Letter Agreement nor any interest hereunder is assignable by either Party without the prior written consent of the other Party, except as follows: (i) either Party may, subject to the terms of this Letter Agreement, assign its rights and obligations under this Letter Agreement in whole to its successor-in-interest in connection with the sale of all or substantially all of its assets to which the License and 

4
​
US-DOCS\131166251.5

 ​

			Commercialization Agreement relates, whether in a merger, acquisition, or similar transaction or series of related transactions, provided that such sale is not primarily for the benefit of its creditors, and (ii) either Party may assign its rights and obligations under this Letter Agreement to any of its Affiliates, provided that such Party will remain liable for all of its rights and obligations under this Letter Agreement. A Party will promptly notify the other Party of any assignment or transfer under the provisions of this Section 5(b) (Assignment of this Letter Agreement). This Letter Agreement will be binding upon the successors and permitted assigns of the Parties and the name of a Party appearing herein will be deemed to include the names of such Party’s successors and permitted assigns to the extent necessary to carry out the intent of this Letter Agreement. Any assignment or attempted assignment by either Party in violation of the terms of this Section 5(b) (Assignment of this Letter Agreement) will be null, void and of no legal effect. 

		(c)	Confidentiality. The terms of this Letter Agreement are deemed “terms of this Agreement” and so “Confidential Information of both Parties” subject to Section 12.1 (Confidentiality; Exceptions) of the License and Commercialization Agreement mutatis mutandis as if such Section were set forth in this Letter Agreement; provided that each Party will be entitled to disclose the terms of this Letter Agreement to the extent permitted in Section 12.2 (Authorized Disclosure) of the License and Commercialization Agreement mutatis mutandis as if such Section were set forth in this Letter Agreement.

		(d)	Severability.  If any one or more of the provisions of this Letter Agreement is held to be invalid or unenforceable by an arbitrator or by any court of competent jurisdiction from which no appeal can be or is taken, then the provision will be considered severed from this Letter Agreement and will not serve to invalidate any remaining provisions hereof.  The Parties will make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering into this Letter Agreement may be realized.  

		(e)	Independent Contractor. Each Party will act solely as an independent contractor, and nothing in this Letter Agreement will be construed to give either Party the power or authority to act for, bind, or commit the other Party in any way.  Nothing herein will be construed to create the relationship of partners, principal and agent, or joint-venture partners between the Parties.

		(f)	Further Actions.  Each Party agrees to execute, acknowledge, and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Letter Agreement.  

		(g)	Interpretation.  Except where the context expressly requires otherwise, (i) the use of any gender herein will be deemed to encompass references to either or both genders, and the use of the singular will be deemed to include the plural (and vice versa), (ii) the words “include”, “includes” and “including” will be deemed to be followed by the phrase “without limitation,” (iii) the word “will” will be construed to have the same meaning and effect as the word “shall,” (iv) any definition of or reference to any agreement, instrument or other document herein will be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (v) any reference herein to any person or entity will be construed to include the person’s or entity’s successors and assigns, (vi) the words “herein,” “hereof,” and “hereunder”, and words of similar import, will be construed to refer to this Letter Agreement in its entirety and not to any particular provision hereof, (vii) all references herein to Sections or Schedules will be construed to refer to Sections or Schedules 

5
​
US-DOCS\131166251.5

 ​

			of this Letter Agreement, and references to this Letter Agreement include all Schedules hereto, (viii) the word “notice” means notice in writing (whether or not specifically stated) and will include notices, consents, approvals and other written communications contemplated under this Letter Agreement, (ix) provisions that require that a Party, the Parties or any committee hereunder “agree,” “consent,” or “approve” or the like will require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (including e-mail, but excluding instant messaging), (x) references to any specific law, rule or regulation, or article, section or other division thereof, will be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof, (xi) the term “or” will be interpreted in the inclusive sense commonly associated with the term “and/or,” and (xii) references to any Sections include Sections and subsections that are part of the related Section (e.g., a section numbered “Section 2.2” would be part of “Section 2”, and references to “Section 2.2” would also refer to material contained in the subsection described as “Section 2.2(a)”)  Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation of this Letter Agreement.  Accordingly, the rule of construction that any ambiguity in this Letter Agreement will be construed against the drafting Party will not apply. 

		(h)	Entire Agreement; Amendment.  This Letter Agreement, the TIGIT Exercise Letter Agreement dated January 9, 2022, and the License and Commercialization Agreement, including the Schedules hereto, set forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings between the Parties existing as of the date hereof with respect to the subject matter hereof.  There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as are set forth herein and therein.  No subsequent alteration, amendment, change or addition to this Letter Agreement will be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party.

		(i)	No Waiver.  Any delay in enforcing a Party’s rights under this Agreement or any waiver as to a particular default or other matter will not constitute a waiver of such Party’s rights to the future enforcement of its rights under this Agreement, except with respect to an express written and signed waiver relating to a particular matter for a particular period of time.

		(j)	Counterparts.  This Letter Agreement may be executed in one or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument.

[Remainder of this page intentionally left blank]
​

6
​
US-DOCS\131166251.5

​

Please sign and return a copy of this Letter Agreement to us to acknowledge each party’s agreement on this matter.  Thank you for all of your assistance.
​
Sincerely,
​
COHERUS BIOSCIENCES, INC.
​
/s/ Dennis M. Lanfear​ ​​ ​​ ​​ ​
Name:Dennis M. Lanfear​ ​​ ​​ ​
Title:Chairman & Chief Executive Officer​ ​
​
​
ACKNOWLEDGED AND AGREED:
​
​
SHANGHAI JUNSHI BIOSCIENCES CO., LTD.
​
/s/ Ning Li​ ​​ ​​ ​​ ​
Name:Ning Li​ ​​ ​​ ​​ ​
Title:CEO​ ​​ ​​ ​​ ​

​
US-DOCS\131166251.5Exhibit 10.1

 

TRANSITION AND GENERAL RELEASE AGREEMENT

 

This Transition and General
Release Agreement (this “Agreement”) is made by and between Bath & Body Works, Inc., a Delaware corporation
(the “Company”), and Andrew M. Meslow (“Executive”) (collectively, the “Parties”)
on this 4th day of May, 2022.

 

WHEREAS, Executive has been
and is currently employed by the Company as its Chief Executive Officer and is also a member of the Company’s Board of Directors
(the “Board”);

 

WHEREAS, Executive has provided
notice to the Company that he wishes to resign his employment and also resign as member of the Board due to health reasons effective as
of May 12, 2022 (the “Resignation Date”);

 

WHEREAS, in connection with
the Parties’ mutual decision for Executive to resign his employment with the Company and membership on the Board, the Parties desire
to enter into this Agreement with respect to the Parties’ respective rights and obligations in connection with such resignation
from employment and membership from the Board, including under Executive’s employment agreement with the Company dated May 15,
2020 (the “Employment Agreement”), and the Confidentiality, Non-Competition and Intellectual Property Agreement with
the Company dated May 15, 2020 (the “Restrictive Covenant Agreement”); and

 

WHEREAS, the Parties wish
to fully and finally settle any and all matters related to Executive’s employment with, and separation of employment from, the Company,
and all other claims controversies, charges, or disputes of any type which may exist or may arise between them, including but not limited
to any claims for compensation or benefits under the Employment Agreement, and any other plans, agreements, or understandings related
to Executive’s compensation for services performed for the Company during the period of Executive’s employment, and under
any contract, plan, policy, practice, or arrangement, past or present, of the Company.

 

NOW THEREFORE, in consideration
of the mutual promises and other good and valuable consideration set forth herein, the receipt and sufficiency of which is hereby acknowledged,
the Parties agree as follows:

 

1.            No
Admission of Liability. It is understood that by entering into this Agreement, neither Executive nor the Company is admitting any
wrongful conduct or violation of law, and that both Executive and the Company have entered into this Agreement solely in the interest
of providing a smooth transition of leadership and resolving all claims and issues which may exist or may arise relating to Executive’s
employment and/or separation of employment from the Company.

 

2.            Termination
of Employment. Effective as of May 12, 2022 (the “Separation Date”), Executive hereby resigns from the position
of Chief Executive Officer of the Company, as a member of the Board, and from any and all other positions and offices with the Company,
including any of its affiliates. Executive agrees and acknowledges that, from and after the Separation Date, Executive shall no longer
be an employee of the Company and shall not hold himself out as an employee of the Company, and Executive will cease performing all job
duties for the Company. Executive agrees that, other than as explicitly provided in and as an effect of this Agreement, Executive is not
entitled to any additional payments, compensation, bonus, severance, equity-based awards, acceleration of any previously granted equity-based
awards, consideration, or benefits of any kind from the Company with regard to Executive’s employment with, or work for, the Company
through the Separation Date. As of the Separation Date, except as provided herein, Executive will no longer be eligible for benefits through
the Company with the exception of certain benefits which may by their explicit terms, remain in force through and after the Separation
Date.

 

    

     

    

 

3.            Equity
Awards. Only the stock options (or any other equity-based award(s), including, without limitation, restricted share units and performance
units) granted to Executive and vested as of the Separation Date, if any, will be exercisable, but only to the extent provided by the
Company’s 2020 Stock Option and Performance Incentive Plan (including any predecessor plan) and applicable award agreement(s) thereunder.
Any equity awards granted to Executive which remain unvested as of the Separation Date will be forfeited pursuant to the terms of such
applicable award agreement(s) for no consideration.

 

4.            Consideration.
In consideration of Executive’s promises, covenants, and release of claims contained herein and the Second Release (defined below),
Executive acknowledges that, subject to and as a result of Executive’s execution of this Agreement (without revocation by Executive
pursuant to Section 17 hereof) and the second release attached hereto as Exhibit B (the “Second Release”)
within thirty (30) days following the Separation Date, the Parties agree as follows (each and collectively, “Consideration”):

 

(a)            the
Company agrees to pay Executive an aggregate cash amount equal to $7,000,000.00, less all amounts required or authorized to be withheld
by law, including all applicable federal, state and local withholding taxes, payable over a twenty-four (24) month period, in accordance
with the normal payroll practices of the Company, commencing on June 3, 2022; and

 

(b)            subject
to Executive’s eligibility for, and proper election of, medical, dental and/or vision continuation coverage under the Consolidated
Omnibus Budget Reconciliation Act (“COBRA”) under the Company’s group health plan, Executive and, if applicable,
Executive’s dependents, shall be permitted to continue coverage under the Company’s group health plan for twenty-four (24)
months (the “Continuation Coverage”) subject to its terms and conditions as in effect from time to time. The Company
will pay the monthly premiums due for the Continuation Coverage for Executive and, if applicable, for Executive’s dependents until
the earliest of (i) the date when Executive becomes eligible for substantially similar health insurance coverage under an employer’s
group health plan in connection with any new employment (regardless of whether such coverage is actually elected), or (ii) the
end of the Continuation Period. Executive shall provide prompt written notice to the Company of the occurrence of the event described
in subsection “(i)” in the preceding sentence, but in no event later than seven (7) calendar days after such occurrence.
In the event the Company’s obligation to pay Executive’s Continuation Coverage premiums under this paragraph terminates because
of the occurrence of the event in subsection “(i)” above, Executive may elect to continue any then remaining COBRA continuation
coverage period at Executive’s sole cost and expense. The Continuation Period shall run concurrently with the required COBRA continuation
coverage period applicable to Executive. Notwithstanding the foregoing, if the Company determines that it cannot provide the foregoing
Continuation Coverage benefit without potentially violating applicable law or having the Continuation Coverage benefit be subject to tax,
the Company will, in lieu thereof, pay Executive an amount equal to the COBRA premium amount for each month, as applicable, which payment
will be taxable, subject to standard payroll deductions and withholdings, and will made at the time such COBRA premium payment would otherwise
have been due to be paid to the Company’s group health plan.

 

    2

     

    

 

Executive acknowledges that the Consideration
provided herein satisfies any and all obligations of the Company to Executive and constitutes consideration in exchange for Executive’s
execution and non-revocation of this Agreement (including for the avoidance of doubt, timely execution and non-revocation of the Second
Release), and that such are payments and benefits to which Executive would not have otherwise been entitled had Executive not executed
this Agreement.

 

Notwithstanding any provision
herein to the contrary, Executive will not be required to satisfy the requirements to execute the Second Release if Executive, in Executive’s
sole discretion, elects to execute this Agreement on or after the Separation Date.

 

5.            General
Waiver and Release. In exchange for the Consideration identified in this Agreement, which Executive acknowledges is in addition to
anything of value to which Executive is already entitled, Executive hereby waives, releases, settles, and forever discharges the Company,
its affiliates, and each of their respective past and present board members, executives, directors, trustees, officers, employees, agents,
insurers, predecessors, successors, attorneys, and any other party associated with the Company (“Releasees”), to the
fullest extent permitted by applicable law, from any and all claims, causes of action, rights, demands, debts, liens, liabilities, or
damages of whatever nature, including negligence, whether known or unknown, suspected or unsuspected, that Executive ever had or may now
have, which have been or could be raised by Executive against any Releasee through the date hereof. Executive’s waiver and release
includes, but is not limited to, all claims, liens, demands, or liabilities arising out of or in any way connected with Executive’s
employment with the Company or the termination of that employment pursuant to any federal, state, or local laws regulating employment
including, but not limited to, claims of race, national origin, ancestry, handicap, disability, religion, marital status, pregnancy, sexual
orientation, gender identity, veteran status, sexual harassment, sex, and age discrimination, retaliation, and all claims under the Civil
Rights Act of 1964, as amended, the Civil Rights Act of 1991, the Employee Retirement Income Security Act, the Rehabilitation Act of 1973,
The Reconstruction Era Civil Rights Act, as amended, the Americans with Disabilities Act of 1990 (“ADA”) and the ADA
Amendments Act of 2008, the Family and Medical Leave Act, the Age Discrimination in Employment Act (“ADEA”), including
without limitation the Older Workers’ Benefit Protection Act (“OWBPA”), the Equal Pay Act, the Fair Labor Standards
Act, the Immigration Control and Reform Act, the Fair Credit Reporting Act, as well as any other common law, federal, state, or local
laws, statutes, or ordinances that can be released. Nothing in this Agreement shall be construed to prevent Executive from participating
in any charge of discrimination filed with the Equal Employment Opportunity Commission (“EEOC”) or similar state agency;
provided, however, that by signing this Agreement, Executive waives the right to recover any monetary damages or attorney
fees from the Releasees in any claim or lawsuit brought by or through the EEOC or similar state agency. If Executive brings an action
or other claim against any of the Releasees in violation of this release, or otherwise materially breaches this Agreement, the Company
or such other of the Releasees shall have the right to set off any and all damages to which it or any of the Releasees may be entitled
against payments or other benefits due to Executive under this Agreement and to recover from Executive their attorneys’ fees and
costs incurred in defending against such action or other claim. Executive agrees that Executive is the only person who is able to assert
any right or claim arising out of Executive’s employment with and separation from the Company. Executive hereby acknowledges that
Executive has not assigned, pledged, or otherwise sold any such rights or claims, nor has Executive relied on any promises other than
those expressly contained in this Agreement. The release of claims under this paragraph shall not apply to any claims that Executive may
have or will have with respect to his vested benefits, ownership of stock, restricted stock, or stock options in the Company or workers
compensation or unemployment benefits from the Company. Executive is hereby advised that the Defend Trade Secrets Act of 2016 provides
immunity from civil and criminal liability under state and federal trade secret laws for any employee who discloses a trade secret in
a lawsuit or other proceeding filed under seal or who discloses a trade secret in confidence to a government official or an attorney for
the sole purpose of reporting or investigating a suspected violation of law.

 

    3

     

    

 

6.            Specific
Waiver and Release under the Age Discrimination in Employment Act and the Older Workers’ Benefit Protection Act. Executive further
expressly and specifically waives any and all rights or claims under the ADEA and the OWBPA (collectively, the “Act”).
Executive acknowledges and agrees that this waiver of any right or claim under the Act (the “Waiver”) is knowing and
voluntary, and Executive further specifically agrees and represents as follows:

 

(a)            that
this Agreement in its entirety, as well as, specifically, this Waiver, is written in a manner that Executive understands;

 

(b)            that
this Waiver specifically relates to rights or claims under the Act;

 

(c)            that
Executive does not waive any rights or claims under the Act that may arise after the Effective Date of this Agreement;

 

(d)            that
Executive waives rights or claims under the Act in exchange for consideration in addition to anything of value to which Executive is already
entitled; and

 

(e)            that
Executive is hereby advised in writing to consult with an attorney prior to executing this Agreement, and that Executive has been, or
has had the opportunity to be, represented by counsel of his choosing at all times relevant herein.

 

7.            No
Known Violations. Executive represents that Executive has not engaged in any conduct that would constitute willful misconduct, gross
negligence, or a violation of the law or any of the Company’s standards of conduct or similar policies. Further, Executive is not
aware of any conduct on the part of any other Company employee that would constitute a violation of the law or any of the Company’s
standards of conduct or similar policies. Additionally, Executive represents that he has not been prevented, prohibited, or in any manner
restricted by the Company from making a full disclosure of any concerns regarding such matters to the Company.

 

8.            Cooperation.
The Parties agree that certain matters in which Executive was involved during his employment and prior to the Separation Date may necessitate
Executive’s cooperation or assistance in the future. After the Separation Date, Executive shall, to the extent reasonably requested
by the Board, cooperate in good faith with the Company and its lawyers to assist the Company in the pursuit or defense of any claim, administrative
charge or cause of action by or against the Company or any of its affiliates, or any internal or external investigation, audit or examination
(except if Executive is adverse to the Company with respect to such matter) as to which Executive has material relevant knowledge by virtue
of Executive’s prior positions with the Company or its affiliates, including providing truthful testimony without the need for a
subpoena. The Company shall (i) reimburse Executive for any reasonable and documented out-of-pocket travel, delivery or similar expenses
incurred by Executive at the Company’s request in order to comply with this paragraph and (ii) from and after the second anniversary
of the Resignation Date, pay to Executive a fee of $1,500.00 per hour of services provided by Executive after such date, if any, in order
to comply with this paragraph. However, Executive will not be entitled to receive any other payments for the performance of Executive’s
obligations under this paragraph. Notwithstanding anything to the contrary in this paragraph, Executive will not be required to cooperate
against Executive’s own legal interests.

 

    4

     

    

 

Executive shall not be entitled
to any other compensation with respect to Executive’s time spent in connection with the performance of Executive’s obligations
under this Section 8. Any reimbursements or in-kind benefits due hereunder shall be provided such that the amount paid in one calendar
year cannot affect the expenses eligible for reimbursement in another calendar year, shall be paid to Executive no later than the last
day of the calendar year after the calendar year in which incurred and any right to reimbursement shall be subject to liquidation or exchange
for another benefit.

 

9.            Restrictive
Covenant Agreement. The Restrictive Covenant Agreement is attached hereto as Exhibit A and incorporated herein by this
reference, subject to the following modifications. The Company and Executive agree and acknowledge that (a) the “Restricted
Period” for purposes of the Restrictive Covenant Agreement shall mean the twenty-four (24) month period following the Separation
Date, and (b) Section 5 of the Restrictive Covenant Agreement shall be modified to read “During the Restricted Period, I
will not, directly or indirectly, without the prior written consent of the Company, own, manage, operate, join, control, be employed by,
consult with or participate in the ownership, management, operation or control of, or be connected with (as a stockholder, partner, or
otherwise), any business, individual, partner, firm, corporation or other entity that substantially competes or plans to compete, directly
or indirectly, with the Company, or any of its products in any country (or part thereof) in the world in which the Company operates, sells
or markets its products, or with respect to which I had responsibility or supervisory authority or learned any Confidential Information;
provided, however, that the “beneficial ownership” by me after my termination of employment with the Company, either individually
or as a member of a “group,” as such terms are used in Rule 13d of the General Rules and Regulations under the Securities
Exchange Act of 1934, as amended, of not more than two percent (2%) of the voting stock of any publicly held corporation shall not be
a violation of this Agreement.” The Restrictive Covenant Agreement shall remain in full force and effect as modified herein
in accordance with its terms following the Separation Date.

 

    5

     

    

 

10.           Binding
Effect. This Agreement shall bind Executive and Executive’s heirs, executors, administrators, personal representatives, attorneys,
dependents, successors, and assigns. Neither this Agreement, nor any right or interest hereunder, shall be assignable by Executive, Executive’s
beneficiaries, or Executive’s legal representatives without the prior written consent of the Company.

 

11.           Final
Resolution. Executive accepts the benefits of this Agreement as full compensation and resolution of any and all claims, as stated
herein, including attorney fees, and covenants that Executive shall not file suit to recover attorney fees or compensation in any form,
except as specifically set forth this Agreement.

 

12.           Return
of Property. Executive affirms and warrants that Executive has returned or will promptly return at such time requested by the Company
to the Company all Company property in a satisfactory condition, including but not limited to, all keys, credit or access cards, equipment,
documents, copies of documents, draft and final reports, materials, studies, disks, computers, and all Company information stored in any
electronic form.

 

13.           Entire
Agreement. This Agreement (including the Second Release), and those agreements which are expressly incorporated herein, set forth
the entire agreement between the Parties and supersede any and all prior agreements or understandings, oral or written, between the Parties.
The terms of this Agreement may not be modified other than in a writing signed by both Parties.

 

14.           Dispute
Resolution; Choice of Law and Forum. If Executive or the Company contends that the provisions of this Agreement are not being complied
with, written notice of alleged non-compliance shall be given to the other party within twenty (20) calendar days of knowledge of the
alleged non-compliance. Such notice must be either hand delivered or received by mail on or before such twentieth (20th) day.
The Party receiving such notice shall have ten (10) business days from receipt of such written notice to resolve the alleged non-compliance
through mutual efforts at conciliation. The Parties may mutually agree in writing upon additional time to endeavor to resolve the alleged
non-compliance. In the event that conciliation fails within the time set forth above, with the exception of a claim for injunctive relief,
the Parties agree to the submission of the dispute(s) to a mutually agreeable arbitrator whose award shall be accepted as final and
binding upon the Parties. If the Parties are unable to agree upon an arbitrator, one shall be selected pursuant to American Arbitration
Association’s Employment Arbitration Rules then in effect. The arbitration shall be held in Columbus, Ohio and the Parties
shall treat the arbitration proceedings as completely confidential. Except as otherwise agreed, the dispute(s) must be presented,
upon the request of either Party, to the arbitrator within twenty (20) calendar days from the date of the failure of conciliation, as
set forth above, and the arbitrator must issue a decision within twenty (20) calendar days thereafter. Prior to making any request for
arbitration, the Party requesting arbitration shall certify to the other in writing that the request is well founded both in law and in
fact. In the event of arbitration instituted under this Agreement, the Parties shall be equally responsible for payment of the arbitrator’s
fees. In any arbitration is instituted under this Agreement, the arbitrator shall have the authority to award any and all other appropriate
damages. This Agreement to arbitrate may be compelled under the Ohio or Federal Arbitration Act. The interpretation and enforcement of
this Agreement shall be governed by the internal laws and judicial decisions of the State of Ohio, without regard to any principles of
conflicts of laws.

 

    6

     

    

 

15.           Severability.
Should any provision of this Agreement, or the application thereof, be held invalid or unenforceable by a court of competent jurisdiction,
the invalid or unenforceable provision, to the extent possible, will be revised to adhere to the intentions of the Parties as valid or
enforceable under the law, and the remainder of this Agreement shall not be affected and shall continue to be valid and enforceable to
the fullest extent permitted by law or equity unless the invalid or unenforceable provisions result in a failure of consideration.

  

16.           Captions.
Captions and headings of this Agreement are intended solely for convenience and no provision of this Agreement is to be construed by reference
to the caption or heading of any section or paragraph.

 

17.           Consideration
and Revocation Periods. Executive acknowledges that Executive is hereby advised of the right to consider this Agreement for twenty-one
(21) days prior to accepting it. Executive may decide to accept this Agreement prior to the expiration of the twenty-one (21) day period.
If Executive chooses to accept this Agreement prior to the expiration of that period, Executive acknowledges doing so freely and voluntarily,
without any coercion or duress from anyone at the Company. Exclusively as this Agreement pertains to Executive’s release of claims
under the ADEA and OWBPA, Executive acknowledges that Executive may revoke the acceptance of this Agreement within seven (7) days
after the date of Executive’s acceptance. Any revocation must be in writing, signed by Executive, and: (a) postmarked within
the seven (7) day revocation period; or (b) noted “hand delivered” and physically delivered prior to the expiration
of the seven (7) day revocation period. If Executive does not revoke this Agreement, it shall be effective on the eighth (8th) day
following Executive’s execution hereof (the “Effective Date”), provided the Company has signed the Agreement
as well by that date.

 

18.           Taxes.
The Company shall withhold from any amounts payable under this Agreement any federal, state or local withholding or other taxes or charges.
Executive agrees to provide any and all information pertaining to Executive upon request as reasonably necessary for the Company and its
affiliates to comply with applicable tax laws. Executive acknowledges that the Company has not provided any advice or opinion to Executive
regarding potential tax liability for the Consideration provided hereunder.

 

    7

     

    

 

19.           Section 409A.

 

(a)            This
Agreement is intended to comply with Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”)
and its corresponding regulations, or an exemption, and payments may only be made under this Agreement upon an event and in a manner permitted
by Section 409A of the Code, to the extent applicable. The payments and benefits under the Agreement are intended to be exempt from
Section 409A of the Code under the “short-term deferral” exception, to the maximum extent applicable, and then under
the “separation pay” exception, to the maximum extent applicable. For purposes of Section 409A of the Code, all payments
to be made upon a termination of employment under this Agreement may only be made upon a “separation from service” within
the meaning of such term under Section 409A of the Code, each payment made under this Agreement shall be treated as a separate payment
and the right to a series of installment payments under this Agreement is to be treated as a right to a series of separate payments. In
no event shall Executive, directly or indirectly, designate the calendar year of payment. Notwithstanding any provision of this Agreement
to the contrary, in no event shall the timing of Executive’s execution of this Agreement or the Second Release, directly or indirectly,
result in Executive designating the calendar year of payment, and if a payment that is “deferred compensation” subject to
Section 409A of the Code and subject to execution of this Agreement could be made in more than one taxable year, payment shall be
made in the later taxable year. All reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance
with the requirements of Section 409A of the Code, including, where applicable, the requirement that (i) any reimbursement is
for expenses incurred during Executive’s lifetime (or during a shorter period of time specified in this Agreement), (ii) the
amount of expenses eligible for reimbursement, or in-kind benefits provided, during a calendar year may not affect the expenses eligible
for reimbursement, or in-kind benefits to be provided, in any other calendar year, (iii) the reimbursement of an eligible
expense will be made on or before the last day of the calendar year following the year in which the expense is incurred, and (iv) the
right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.

 

(b)            Notwithstanding
any provision in this Agreement to the contrary, if Executive is a “specified employee” (as defined in Section 409A of
the Code) and it is necessary to postpone the commencement of any payments otherwise payable pursuant to this Agreement as a result of
such separation from service to prevent any accelerated or additional tax under Section 409A of the Code, then Company will postpone
the commencement of the payment of any such payments hereunder (without any reduction in such payments ultimately paid or provided to
Executive) that are not otherwise exempt from Section 409A of the Code, until the first payroll date that occurs after the date that
is six (6) months following Executive’s separation from service with Company. If any payments are postponed due to such requirements,
such postponed amounts will be paid in a lump sum to Executive on the first payroll date that occurs after the date that is six (6) months
following Executive’s separation from service with Company.

 

(c)            Company
makes no representation or warranty and shall have no liability to Executive or any other person if any provisions of this Agreement are
determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions
of, Section 409A of the Code.

 

20.           Whistleblower
Protections. Nothing in this Agreement or any other prior agreement between Executive and the Company prevents Executive from reporting
possible violations of law or regulation to any governmental agency or entity in accordance with the provisions of and rules promulgated
under Section 21F of the Securities Exchange Act of 1934 or Section 806 of the Sarbanes-Oxley Act of 2002, or any other whistleblower
protection provisions of state or federal law or regulation (including the right to receive an award for information provided to any such
government agencies).

 

    8

     

    

 

21.           Notices.
All notices, demands and other communications under this Agreement shall be given in writing and shall be personally delivered; or sent
by registered or certified U.S. mail, return receipt requested and postage prepaid; or by private overnight mail courier service, as follows:

 

If to the Company:

 

Bath & Body Works, Inc. 

Three Limited Parkway 

Columbus, OH 43230 

Attention: Chief Legal Officer

 

If to Executive:

 

The latest address in the Company’s
records,

 

or to such other person or address as a party
shall have specified by notice in writing to the other party. If personally delivered, such communication shall be deemed delivered upon
actual receipt; if sent by U.S. mail, such communication shall be deemed delivered as of the date of delivery indicated on the receipt
issued by the relevant postal service or, if the addressee fails or refuses to accept delivery, as of the date of such failure or refusal;
and if sent by overnight courier, such communication shall be deemed delivered upon receipt. Change of contact information may be effected
by delivery of notice to the other parties in the manner specified in this section.

 

22.           Counterparts;
Electronic Execution. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original,
but all of which, when taken together, shall constitute one and the same final Agreement. Signatures to this Agreement may be delivered
by means of electronic transmission, and all such signatures so delivered shall be deemed to be original signatures for all purposes hereunder.

 

By signing this Agreement,
Executive agrees that this Agreement is written in a manner calculated to be understood by Executive, that Executive has carefully reviewed
all of the terms and conditions of this Agreement, and that Executive has had a reasonable period of time to consider this Agreement.
By signing this Agreement, Executive understands that Executive has released all claims against the Company and its affiliates, including,
without limitation, any and all claims for damages and payment of attorneys’ fees, except as specifically set forth in this Agreement.
Executive acknowledges that the consideration Executive has received in connection with this Agreement is a benefit that Executive is
not otherwise entitled to. Executive enters into this Agreement knowingly, voluntarily, without any coercion or undue influence of any
kind, and after a full and fair opportunity to consult with counsel, if desired. Similarly, the Company enters into this Agreement knowingly,
voluntarily, without any coercion or undue influence of any kind, and after a full and fair opportunity to consult with its counsel.

 

If this Agreement is not
executed and delivered by Executive, and does not become irrevocable, by June 3, 2022, it shall be deemed null and void.

 

[Signature page follows. Remainder of page left
intentionally blank.]

 

    9

     

    

 

IN WITNESS WHEREOF, the Parties
have executed this Transition and General Release Agreement as of the date(s) set forth below to be effective as of the Effective
Date.

 

	 	EXECUTIVE:	 
	 	 	 
	 	 	 
	 	/s/
    Andrew M. Meslow	 
	 	Andrew
    M. Meslow	 
	 	 	 
	 	Date:
    May 4, 2022	 
	 	 	 
	 	COMPANY:	 
	 	 	 
	 	 	 
	 	By:
    	/s/
    Sarah E. Nash	 
	 	 	Sarah
    E. Nash, Executive Chair	 
	 	 	 
	 	Date: May 4,
    2022	 

 

[Signature page to Transition and General
Release Agreement]

 

    10

     

    

 

Exhibit A 

to 

Transition and General Release Agreement

 

[Confidentiality, Non-Competition and Intellectual
Property Agreement]

 

CONFIDENTIALITY, NON-COMPETITION AND INTELLECTUAL PROPERTY
AGREEMENT

 

As an Associate
of a subsidiary of L Brands, Inc. (collectively, the "Company"), I have access to or may develop trade secrets, intellectual
property, and other confidential or proprietary information ("Confidential Information") of the Company.

 

THEREFORE, in consideration
of my employment or continued employment with the Company and my right to participate in the Company's Stock Option and Performance Incentive
Plan, and the Cash Incentive Compensation Performance Plan, as amended, and in recognition of the highly competitive nature of the business
conducted by the Company, I agree as follows:

 

		1.	I will at all times during and after my employment with the Company faithfully
hold the Company's Confidential information in the strictest confidence, and I will use my best efforts and highest diligence to guard
against its disclosure to anyone other than as required in the performance of my duties to the Company. I will not use Confidential Information
for my personal benefit or for the benefit of any competitor of the Company or other person. I understand that Confidential Information
includes all information and materials relating to Intellectual Property, as defined below, the Company's trade secrets and all information
relating to the Company that the Company has not made available to the public. By way of example, Confidential Information includes information
about the Company's products, designs, processes, advertising, marketing, promotional plans, technical procedures, strategies, financial
information, and many other types of information and materials. Upon termination of my employment with the Company, regardless of the
reason for such termination, I will return to the Company all documents and other materials of any kind that contain Confidential Information.
I will not use any confidential information of any third party, including any prior employer, in the course of my work for the Company.
This provision does not prohibit me from cooperating with the EEOC or any other state or local fair employment practices agency. This
provision also does not prohibit me from reporting possible violations of federal or state law or regulations to any governmental entity,
including but not limited to the Department of Justice and the Securities and Exchange Commission, or from making other disclosures protected
under applicable whistleblower provisions of federal or state law or regulations.

 

		2.	If I decide to resign my employment with the Company, I will provide the Company with thirty (30) days prior written notice.

 

		3.	During the Restricted Period (as described below), I will not, directly or indirectly,
solicit, induce or attempt to influence any employee to leave the employment of the Company, nor will I in any way assist anyone else
in doing so. Further, during the Restricted Period, I will not, either directly or indirectly, alone or in conjunction with another party,
interfere with or harm, or attempt to interfere with or harm, the relationship of the Company with any person who at any time was an employee,
customer or supplier of the Company, or otherwise had a business relationship with the Company.

 

The “Restricted
Period” means the period I am employed by the Company plus the longer of (a) one (1) year from the termination date or (b) the
period during which I receive salary continuation set forth in any employment agreement providing for severance or termination
benefits in connection with a termination of employment.

 

    11

     

    

 

		4.	I agree that all inventions, designs and ideas conceived, produced, created, or
reduced to practice, either solely or jointly with others, during my employment with the Company, including those developed on my own
time, which relate to or are useful in the Company's business ("Intellectual Property") shall be owned solely by the Company.
I understand that whether in preliminary or final form, such Intellectual Property includes, for example, all ideas, inventions, discoveries,
designs, innovations, improvements, trade secrets, and other intellectual property. All Intellectual Property is either work made for
hire for the Company within the meaning of the U. S. Copyright Act, or, if such Intellectual Property is determined not to be work made
for hire, then I irrevocably assign all right, title and interest in and to the Intellectual Property to the Company, including all copyrights,
patents, and/or trademarks. I will, without any additional consideration, execute all documents and take all other actions needed to convey
my complete ownership of the Intellectual Property to the Company so that the Company may own and protect such Intellectual Property and
obtain patent, copyright and trademark registrations for it. I agree that the Company may alter or modify the Intellectual Property at
the Company's sole discretion, and I waive all right to claim or disclaim authorship. I represent and warrant that any Intellectual Property
that I assign to the Company, except as otherwise disclosed in writing at the time of assignment, will be my sole, exclusive, original
work. I have not previously invented any Intellectual Property, or I have advised the Company in writing of any prior inventions or ideas.

 

		5.	During the Restricted Period, I will not, directly or indirectly, without the prior
written consent of the Company, own, manage, operate, join, control, be employed by, consult with or participate in the ownership, management,
operation or control of, or be connected with (as a stockholder, partner, or otherwise), any business, individual, partner, firm, corporation
or other entity that substantially competes or plans to compete, directly or indirectly, with the Company, or any of its products; provided,
however, that the “beneficial ownership” by me after my termination of employment with the Company, either individually or
as a member of a “group,” as such terms are used in Rule 13d of the General Rules and Regulations under the Securities Exchange
Act of 1934, as amended, of not more than two percent (2%) of the voting stock of any publicly held corporation shall not be a violation
of this Agreement.

 

		6.	I understand that the Company is entitled, in addition to other remedies, to obtain
an injunction against any potential or actual violation of this Agreement. Further, I understand that nothing in this Agreement shall
cancel or modify any right I have to receive compensation upon my termination of employment that has been agreed to in any previous or
contemporaneous agreement.

 

    12

     

    

 

		7.	This Agreement cannot be changed in any way unless the Company and you agree in
a signed writing and this Agreement will be governed by and interpreted in accordance with Ohio law.

 

	By:	     /s/ Michael G. Morris 	5/16/20	 
	 	 	Date Signed	 
	 	 
	EXECUTIVE	 
	 	 
	By:	     /s/ Andrew Meslow 	5/15/20	 
	 	     Andrew Meslow 	Date Signed	 

 

    13

     

    

 

Exhibit B 

to

 

Transition and General Release Agreement

 

RELEASE OF CLAIMS

 

This General Release of Claims
(this “Release”) is executed by Andrew M. Meslow (the “Executive”) on ______________, 2022, in consideration
of the compensation and benefits set forth in the Transition and General Release Agreement (the “Agreement”) entered
into by and between Executive and Bath & Body Works, Inc., a Delaware corporation (the “Company”) (the
Company and Executive collectively referred to herein as the “Parties”) on May 4, 2022. All capitalized terms
used in this Release and not otherwise defined herein are as defined in the Agreement.

 

1.        
     Release. In consideration of the Consideration set forth in the
Agreement and the Company’s promises in the Agreement:

 

(a)            Executive
hereby waives, releases, settles, and forever discharges the Company, its affiliates, and each of their respective past and present board
members, executives, directors, trustees, officers, employees, agents, insurers, predecessors, successors, attorneys, and any other party
associated with the Company (“Releasees”), to the fullest extent permitted by applicable law, from any and all claims,
causes of action, rights, demands, debts, liens, liabilities, or damages of whatever nature, including negligence, whether known or unknown,
suspected or unsuspected, that Executive ever had or may now have, which have been or could be raised by Executive against any Releasee
through the date hereof. Executive’s waiver and release includes, but is not limited to, all claims, liens, demands, or liabilities
arising out of or in any way connected with Executive’s employment with the Company or the termination of that employment pursuant
to any federal, state, or local laws regulating employment including, but not limited to, claims of race, national origin, ancestry, handicap,
disability, religion, marital status, pregnancy, sexual orientation, gender identity, veteran status, sexual harassment, sex, and age
discrimination, retaliation, and all claims under the Civil Rights Act of 1964, as amended, the Civil Rights Act of 1991, the Employee
Retirement Income Security Act, the Rehabilitation Act of 1973, The Reconstruction Era Civil Rights Act, as amended, the Americans with
Disabilities Act of 1990 (“ADA”) and the ADA Amendments Act of 2008, the Family and Medical Leave Act, the Age Discrimination
in Employment Act (“ADEA”), including without limitation the Older Workers’ Benefit Protection Act (“OWBPA”),
the Equal Pay Act, the Fair Labor Standards Act, the Immigration Control and Reform Act, the Fair Credit Reporting Act, as well as any
other common law, federal, state, or local laws, statutes, or ordinances that can be released. Nothing in this Release shall be construed
to prevent Executive from participating in any charge of discrimination filed with the Equal Employment Opportunity Commission (“EEOC”)
or similar state agency; provided, however, that by signing this Release, Executive waives the right to recover any monetary damages or
attorney fees from the Releasees in any claim or lawsuit brought by or through the EEOC or similar state agency. If Executive brings an
action or other claim against any of the Releasees in violation of this release, or otherwise materially breaches this Release, the Company
or such other of the Releasees shall have the right to set off any and all damages to which it or any of the Releasees may be entitled
against payments or other benefits due to Executive under this Release and to recover from Executive their attorneys’ fees and costs
incurred in defending against such action or other claim. Executive agrees that Executive is the only person who is able to assert any
right or claim arising out of Executive’s employment with and separation from the Company. Executive hereby acknowledges that Executive
has not assigned, pledged, or otherwise sold any such rights or claims, nor has Executive relied on any promises other than those expressly
contained in this Release. The release of claims under this paragraph shall not apply to any claims that Executive may have or will have
with respect to his vested benefits, ownership of stock, restricted stock, or stock options in the Company or workers compensation or
unemployment benefits from the Company. Executive is hereby advised that the Defend Trade Secrets Act of 2016 provides immunity from civil
and criminal liability under state and federal trade secret laws for any employee who discloses a trade secret in a lawsuit or other proceeding
filed under seal or who discloses a trade secret in confidence to a government official or an attorney for the sole purpose of reporting
or investigating a suspected violation of law.

 

    14

     

    

 

6.            Specific
Waiver and Release under the Age Discrimination in Employment Act and the Older Workers’ Benefit Protection Act. Executive further
expressly and specifically waives any and all rights or claims under the ADEA and the OWBPA (collectively, the “Act”). Executive
acknowledges and agrees that this waiver of any right or claim under the Act (the “Waiver”) is knowing and voluntary, and
Executive further specifically agrees and represents as follows:

 

(a)           that
this Release in its entirety, as well as, specifically, this Waiver, is written in a manner that Executive understands;

 

(b)          that
this Waiver specifically relates to rights or claims under the Act;

 

(c)          that
Executive does not waive any rights or claims under the Act that may arise after the Release Effective Date (defined below);

 

(d)          that
Executive waives rights or claims under the Act in exchange for consideration in addition to anything of value to which Executive is already
entitled; and

 

(e)           that
Executive is hereby advised in writing to consult with an attorney prior to executing this Release, and that Executive has been, or has
had the opportunity to be, represented by counsel of his choosing at all times relevant herein.

 

2.            Consideration
and Revocation Periods. Executive acknowledges that Executive is hereby advised of the right to consider this Release for twenty-one
(21) days prior to accepting it. Executive may decide to accept this Release prior to the expiration of the twenty-one (21) day period.
If Executive chooses to accept this Release prior to the expiration of that period, Executive acknowledges doing so freely and voluntarily,
without any coercion or duress from anyone at the Company. Exclusively as this Release pertains to Executive’s release of claims
under the ADEA and OWBPA, Executive acknowledges that Executive may revoke the acceptance of this Release within seven (7) days after
the date of Executive’s acceptance. Any revocation must be in writing, signed by Executive, and: (a) postmarked within the
seven (7) day revocation period; or (b) noted “hand delivered” and physically delivered prior to the expiration
of the seven (7) day revocation period. If Executive does not revoke this Release, it shall be effective on the eighth (8th) day
following Executive’s execution hereof (the “Release Effective Date”).

 

    15

     

    

 

3.            Whistleblower
Protections. Nothing in this Release or any other prior agreement between Executive and the Company prevents Executive from reporting
possible violations of law or regulation to any governmental agency or entity in accordance with the provisions of and rules promulgated
under Section 21F of the Securities Exchange Act of 1934 or Section 806 of the Sarbanes-Oxley Act of 2002, or any other whistleblower
protection provisions of state or federal law or regulation (including the right to receive an award for information provided to any such
government agencies).

 

4.            Representations
and Acknowledgments. Executive acknowledges and agrees that all representations and acknowledgements made by Executive in the Agreement
remain correct, true and valid as of the date of the Release Effective Date.

 

EXECUTIVE ACKNOWLEDGES THAT
EXECUTIVE HAS CAREFULLY READ THIS RELEASE AND UNDERSTAND ALL OF ITS TERMS, INCLUDING THE FULL AND FINAL RELEASE OF CLAIMS SET FORTH
ABOVE.

 

EXECUTIVE FURTHER ACKNOWLEDGES
THAT THE CONSIDERATION PAYABLE TO EXECUTIVE UNDER THE AGREEMENT REPRESENT CONSIDERATION FOR SIGNING THIS RELEASE AND ARE NOT SALARY, WAGES
OR BENEFITS TO WHICH EXECUTIVE WAS ALREADY ENTITLED. EXECUTIVE UNDERSTANDS AND ACKNOWLEDGES THAT EXECUTIVE WILL NOT RECEIVE THE CONSIDERATION
SPECIFIED IN THE AGREEMENT UNLESS EXECUTIVE EXECUTES THIS RELEASE AND DO NOT REVOKE THIS RELEASE WITHIN THE TIME PERIOD PERMITTED HEREAFTER
OR BREACH THIS RELEASE.

 

EXECUTIVE FURTHER ACKNOWLEDGES
THAT EXECUTIVE HAS VOLUNTARILY ENTERED INTO THIS RELEASE; THAT EXECUTIVE HAS NOT RELIED UPON ANY REPRESENTATION OR STATEMENT, WRITTEN
OR ORAL, NOT SET FORTH IN THIS RELEASE; THAT EXECUTIVE HAS BEEN GIVEN THE OPPORTUNITY TO HAVE THIS RELEASE REVIEWED BY EXECUTIVE’S
ATTORNEY; AND THAT EXECUTIVE HAS BEEN ENCOURAGED BY THE COMPANY TO DO SO.

 

[Signature Page Follows]

 

    16

     

    

 

IN WITNESS HEREOF, and intending
to be legally bound, Executive has hereunto set Executive’s hand.

 

		Executive:
	 	 
	 	 
	 	Andrew
M. Meslow
	 	 
	 	Date:	 

 

    15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}]]